# Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

> **NCT02184572** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1742 (actual)

## Conditions studied

- Measles; Mumps; Rubella
- Measles-Mumps-Rubella Vaccine

## Interventions

- **BIOLOGICAL:** Priorix
- **BIOLOGICAL:** M-M-R II
- **BIOLOGICAL:** Varivax
- **BIOLOGICAL:** Havrix
- **BIOLOGICAL:** Prevnar 13

## Key facts

- **NCT ID:** NCT02184572
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-25
- **Primary completion:** 2015-08-14
- **Final completion:** 2015-12-22
- **Target enrollment:** 1742 (ACTUAL)
- **Last updated:** 2021-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02184572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02184572, "Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02184572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*